Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Solidly Positive Phase III Data Boost Keryx’ Struggling Iron Drug Auryxia

This article was originally published in The Pink Sheet Daily

Executive Summary

Keryx set to pursue expanded FDA labeling of its phosphate binder Auryxia to pre-dialysis patients with iron deficiency, a patient population already approved for treatment in Europe.

Advertisement

Related Content

Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission
Keryx Aims For Ironclad Hold On Hyperphosphatemia Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel